Novogen Announces 'Cantraxil Plus a Standard-of-Care- Platinum Shown to Prolong Survival in an Animal Model of Recurrent Ovarian Cancer', Then Retracts Announcement

Novogen retracted the following announcement, "following a mistaken understanding of which data was to be presented." Novogen said "Despite this clarification, the scientific data announced remains accurate and relevant, the details of which will be disclosed on a separate occasion.": Novogen Ltd,

, and Yale University today disclosed key pre-clinical data generated in an animal model of recurrent ovarian cancer suggesting that the experimental anti-cancer drug, Cantrixil, may have utility as an adjuvant therapy when dosed in combination with platinum-based drugs. The data was presented by Dr Ayesha Alvero of Yale Medical School to the American Association for Cancer Research (AACR) Advances in Ovarian Cancer Research: Exploiting Vulnerabilities special conference in Orlando Florida as a poster (A61) on October 18, 2015 (Poster session A at 5:30 pm). Professor Gil Mor, Director Division of Reproductive Services at Yale University, said "Previous studies from our laboratory have shown that conventional chemotherapy is not effective against Ovarian Cancer Stem Cells [OCSC] and cannot prevent recurrence. Our finding that Cantrixil, by targeting OCSC, can prevent recurrence in vivo as maintenance therapy or in combination with chemotherapy provides an opportunity for developing new therapeutic strategies that may improve survival in ovarian cancer patients". David Brown PhD, Novogen's Chief Scientific Officer, said "With the reporting of these data, we have now completed our designated pharmacology studies demonstrating Cantrixil proof-of-concept. We remain on track to complete the requisite safety studies for our Cantrixil IND application." "Following a final review of the Safety Data Package and approval of the Phase 1 clinical protocol by the Cantrixil Study Committee, we will submit the necessary documentation to our Australian trial site, Human Research Ethics Committees, with a view to opening a Phase 1 trial in Australia in 2016. We also intend to open a Phase 1 trial site in the USA once Cantrixil has been granted IND status by the US FDA," Dr Brown said.